Evidence map›Paper›PMID 42148097›Full record

ArticleFrontiers in immunology2026

Preclinical evaluation of a bivalent conjugate vaccine against

Renzo Alfini, Roberta Di Benedetto, Martina Carducci, Vikram Paradkar, Hanuman Mallubhotla, Santosh Renukuntla, Dharmeshkumar Patel, Senthilkumar Manoharan, Mallikarjuna Panchakshari, Mahesh Kyasani and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Renzo AlfiniGSK Vaccines Institute for Global Health, Siena, Italy.
Roberta Di BenedettoGSK Vaccines Institute for Global Health, Siena, Italy.
Martina CarducciGSK Vaccines Institute for Global Health, Siena, Italy.
Vikram ParadkarBiological E Limited, Hyderabad, India.
Hanuman MallubhotlaBiological E Limited, Hyderabad, India.
Santosh RenukuntlaBiological E Limited, Hyderabad, India.
Dharmeshkumar PatelBiological E Limited, Hyderabad, India.
Senthilkumar ManoharanBiological E Limited, Hyderabad, India.
Mallikarjuna PanchakshariBiological E Limited, Hyderabad, India.
Mahesh KyasaniBiological E Limited, Hyderabad, India.
Nupur SenguptaBiological E Limited, Hyderabad, India.
Laura B MartinGSK Vaccines Institute for Global Health, Siena, Italy.
Omar RossiGSK Vaccines Institute for Global Health, Siena, Italy.
Simona RondiniGSK Vaccines Institute for Global Health, Siena, Italy.
Carlo GiannelliGSK Vaccines Institute for Global Health, Siena, Italy.
Francesca MicoliGSK Vaccines Institute for Global Health, Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: To create the bivalent vaccine, the Results: The newly developed bivalent vaccine was stable over time, when stored at 2-8 °C. A slight increase of free O:2 was detected, but remained below 15% after 1 year of storage. In preclinical models, the bivalent formulation elicited strong immune responses against both antigens, higher than the corresponding unconjugated polysaccharides. These results have guided the selection of the formulations to be tested in clinical studies. Conclusions: This vaccine has the potential to broaden protection against enteric fever, particularly in high-incidence regions. Further clinical trials are ongoing to confirm efficacy and safety in humans.

Indexed as

Paratyphoid FeverSalmonella paratyphi ASalmonella typhiTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, ConjugateAnimalsAntibodies, BacterialBacterial ProteinsFemaleHumansImmunogenicity, VaccineMiceO AntigensAntibodies, BacterialBacterial ProteinsCRM197 (non-toxic variant of diphtheria toxin)O AntigensTyphoid-Paratyphoid VaccinesVaccines, Conjugate3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) linkageconjugation chemistryglycoconjugateSalmonella Paratyphi ASalmonella Typhivaccine

Identifiers

PMID42148097
PMCPMC13176246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.